I Know First Review: May 17th, 2016

I Know First Review

The stocks selected here are the top performing stocks from I Know First: Pharma Package Forecast for the last three 3 days found in the article titled “Short Term Trading Stocks” This forecast is part of the Pharma Stocks package, as one of I Know First’s quantitative investment solutions. The I Know First Average return for the long position was 10.25% over the 3 days time period outperforming the S&P 500’s 0.12% return by a wide margin.

I Know First Review

Learn how to read the predictions: Instructions

Learn how to strategize with the forecast: Algorithmic Trading Strategies

Please, note-for trading decisions use the most recent forecast.


Medivation logoSignal : 24.06

Predictability : 0.16

Return : 1.53%


Medivation blends a unique business model with an expert team to bring promising medical technologies from the lab bench to the patient bedside. Our enzalutamide clinical development program addresses a large market with significant unmet medical needs.On May 16, 2016, members of the executive committee of Medivation, Inc transmitted a summary of certain key messages regarding the business of the Company to members of the Company’s management team for use by such managers in discussions with employees.


heska logoSignal : 9.86

Predictability : 0.07

Return : -0.54%


Heska Corporation develops, manufactures, markets, sells, and supports veterinary products for canine and feline companion animal health markets in the United States, Europe, and internationally. The company operates through two segments, Core Companion Animal Health; and Other Vaccines, and Pharmaceuticals and Products.


rgnr lohoSignal : 6.56

Predictability : 0.17

Return : 7.20%


Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Its marketed products include EYLEA injection for the treatment of neovascular age-related macular degeneration and diabetic macular edema. The company released its 1Q16 on May 5 ,2016. Following the earnings disappointment , Wall Street analysts revised their target prices for the company. REGN’S 12-month target price was downgraded from $523.80 On February 9, 2016, to $472.60 On May 5, 2016.

KERYX LOGOSignal : 6.27

Predictability : 0.22

Return : 6.74%


Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on providing therapies for patients with renal disease in the United States. Its lead product Auryxia (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate in the gastrointestinal tract and form non-absorbable complexes, as well as treats iron deficiency anemia.


Biomarin logoSignal : 5.06

Predictability : 0.12

Return : 8.37%


BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder; Naglazyme. On may 16th , ABSCI announced today the appointment of Daniel Gold to ABSCI’s board of directors. Dr. Gold has served in senior management roles at several leading biotechnology companies and currently serves as Vice President of process Sciences at BioMarin.


Allergan_LogoSignal : 4.76

Predictability : 0.12

Return : 4.17%


Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Brands, US Medical Aesthetics, International Brands, and Anda Distribution segments. On Monday 16th , Pfizer said that it would buy Anacor pharmaceutical for about $4.5 billion as it turns to smaller deals after walking away from its scuttled acquisition of Allergan PLC.


Signal : 4.50

Predictability : 0.11

Return : 7.67%


Peregrine Pharmaceuticals, Inc., a biopharmaceutical company, researches and develops monoclonal antibodies for the treatment and diagnosis of cancer in the United States and internationally. Recently filed form 8-k Notice of Delisting or Failure to Satisfy a Continued Listing. They have not been able to comply with the listing requirements and their stock has fallen for the previous 30 business days under the minimum $1 per share requirement for continued listing on Nasdaq.


Signal : 4.31

Predictability : 0.14

Return : -0.68%


Herbalife Ltd., a nutrition company, develops and sells weight management, healthy meals and snacks, sports and fitness, energy and targeted nutritional products, and personal care products. On May 11, it was announced that Perishing Square’s closed-end fund is getting close to negative returns.


Signal : 4.29

Predictability : 0.08

Return : 63.85%


Anacor Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. It markets KERYDIN (tavaborole) topical solution for the treatment of onychomycosis of the toenails. The giant in pharmaceuticals Pfizer Inc. (PFE) recently announced their desire of acquiring Anacor biopharmaceutical company for $99.25 per share or a total of about $5.2 billion.


Signal : 4.14

Predictability : 0.13

Return : 4.21%


ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. The company focuses on producing controlled substances, anti-cancer (oncolytic), hormones and steroids, and complex formulations.